Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer
2008-006430-10Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dovitinib in breast cancer (4 arms), sponsored by Novartis. Primary endpoint: Overall response rate. Started May 2009; status: terminated.
02
Drugs
dovitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-006430-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006430-10.